Building upon this, CPMV-based in situ vaccination synergizes with CD47-blocking antibodies through dual-pathway activation: CPMV recruits and primes phagocytes, while CD47 blockade disables “don’t eat me” signals, enhancing macrophage-mediated tumor cell phagocytosis and bridging innate and adaptive immunity [99]. The gene discussed is CD47; the disease is neoplasm.